Merck & Co. Inc. plans to create 350 new jobs by building a biologics manufacturing facility at its Swords site near Dublin, Ireland, FiercePharma reported Feb. 14.

Biologics are large molecules derived from natural sources, such as microorganisms or plant or animal cells.

The company plans to use the new facility to produce its blockbuster cancer drug Keytruda.

Merck expects the plant to be ready by 2021 and start producing commercial products the next year, the news outlet reported.